Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39


A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196.

Leighl NB, Tsao MS, Liu G, Tu D, Ho C, Shepherd FA, Murray N, Goffin JR, Nicholas G, Sakashita S, Chen Z, Kim L, Powers J, Seymour L, Goss G, Bradbury PA.

Oncotarget. 2017 Jun 28;8(41):69651-69662. doi: 10.18632/oncotarget.18753. eCollection 2017 Sep 19.


Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).

Labbé C, Cabanero M, Korpanty GJ, Tomasini P, Doherty MK, Mascaux C, Jao K, Pitcher B, Wang R, Pintilie M, Leighl NB, Feld R, Liu G, Bradbury PA, Kamel-Reid S, Tsao MS, Shepherd FA.

Lung Cancer. 2017 Sep;111:23-29. doi: 10.1016/j.lungcan.2017.06.014. Epub 2017 Jun 24.


Uncommon EGFR mutations in advanced non-small cell lung cancer.

O'Kane GM, Bradbury PA, Feld R, Leighl NB, Liu G, Pisters KM, Kamel-Reid S, Tsao MS, Shepherd FA.

Lung Cancer. 2017 Jul;109:137-144. doi: 10.1016/j.lungcan.2017.04.016. Epub 2017 Apr 27. Review.


Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer.

Doherty MK, Korpanty GJ, Tomasini P, Alizadeh M, Jao K, Labbé C, Mascaux CM, Martin P, Kamel-Reid S, Tsao MS, Pintilie M, Liu G, Bradbury PA, Feld R, Leighl NB, Chung C, Shepherd FA.

Radiother Oncol. 2017 May;123(2):195-202. doi: 10.1016/j.radonc.2017.03.007. Epub 2017 Mar 28.


HER2 Transmembrane Domain Mutations: Rare New Target for Non-Small Cell Lung Cancer Therapy.

Notsuda H, Bradbury PA, Tsao MS.

J Thorac Oncol. 2017 Mar;12(3):422-424. doi: 10.1016/j.jtho.2017.01.007. No abstract available.


Real-World EQ5D Health Utility Scores for Patients With Metastatic Lung Cancer by Molecular Alteration and Response to Therapy.

Labbé C, Leung Y, Silva Lemes JG, Stewart E, Brown C, Cosio AP, Doherty M, O'Kane GM, Patel D, Cheng N, Liang M, Gill G, Rett A, Naik H, Eng L, Mittmann N, Leighl NB, Bradbury PA, Shepherd FA, Xu W, Liu G, Howell D.

Clin Lung Cancer. 2017 Jul;18(4):388-395.e4. doi: 10.1016/j.cllc.2016.12.015. Epub 2016 Dec 28.


BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial.

Liu G, Cuffe S, Liang S, Azad AK, Cheng L, Brhane Y, Qiu X, Cescon DW, Bruce J, Chen Z, Cheng D, Patel D, Tse BC, Laurie SA, Goss G, Leighl NB, Hung R, Bradbury PA, Seymour L, Shepherd FA, Tsao MS, Chen BE, Xu W, Reisman DN.

Clin Cancer Res. 2017 May 15;23(10):2460-2470. doi: 10.1158/1078-0432.CCR-16-1640. Epub 2016 Nov 8.


A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207.

Wheatley-Price P, Chu Q, Bonomi M, Seely J, Gupta A, Goss G, Hilton J, Feld R, Lee CW, Goffin JR, Maksymiuk A, Murray N, Hagerman L, Bradbury PA.

J Thorac Oncol. 2016 Nov;11(11):2018-2021. doi: 10.1016/j.jtho.2016.06.024. Epub 2016 Jul 20.


ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients.

Cuffe S, Azad AK, Qiu X, Qiu X, Brhane Y, Kuang Q, Marsh S, Savas S, Chen Z, Cheng D, Leighl NB, Goss G, Laurie SA, Seymour L, Bradbury PA, Shepherd FA, Tsao MS, Chen BE, Xu W, Liu G.

Cancer Epidemiol. 2016 Apr;41:50-6. doi: 10.1016/j.canep.2015.12.012. Epub 2016 Jan 24.


Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

Zer A, Ding K, Lee SM, Goss GD, Seymour L, Ellis PM, Hackshaw A, Bradbury PA, Han L, O'Callaghan CJ, Tsao MS, Shepherd FA.

J Thorac Oncol. 2016 Mar;11(3):312-23. doi: 10.1016/j.jtho.2015.11.010. Epub 2015 Dec 31.


Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial.

Addison CL, Ding K, Seymour L, Zhao H, Laurie SA, Shepherd FA, Goss GD, Bradbury PA.

Lung Cancer. 2015 Nov;90(2):288-95. doi: 10.1016/j.lungcan.2015.09.004. Epub 2015 Sep 16.


Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.

Foster NR, Renfro LA, Schild SE, Redman MW, Wang XF, Dahlberg SE, Ding K, Bradbury PA, Ramalingam SS, Gandara DR, Shibata T, Saijo N, Vokes EE, Adjei AA, Mandrekar SJ.

J Thorac Oncol. 2015 Jul;10(7):1099-106. doi: 10.1097/JTO.0000000000000548.


Angiotensin-Converting Enzyme and Aldosterone Serum Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group Study BR.24.

Bar J, Ding K, Zhao H, Han L, Laurie SA, Seymour L, Addison CL, Shepherd FA, Goss GD, Dimitroulakos J, Bradbury PA.

Clin Lung Cancer. 2015 Nov;16(6):e189-201. doi: 10.1016/j.cllc.2015.05.002. Epub 2015 May 13.


A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195.

Eigl BJ, North S, Winquist E, Finch D, Wood L, Sridhar SS, Powers J, Good J, Sharma M, Squire JA, Bazov J, Jamaspishvili T, Cox ME, Bradbury PA, Eisenhauer EA, Chi KN.

Invest New Drugs. 2015 Aug;33(4):969-76. doi: 10.1007/s10637-015-0252-4. Epub 2015 May 19.


Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial.

Ellis PM, Shepherd FA, Millward M, Perrone F, Seymour L, Liu G, Sun S, Cho BC, Morabito A, Leighl NB, Stockler MR, Lee CW, Wierzbicki R, Cohen V, Blais N, Sangha RS, Favaretto AG, Kang JH, Tsao MS, Wilson CF, Goldberg Z, Ding K, Goss GD, Bradbury PA; NCIC CTG; Australasian Lung Cancer Trials Group; NCI Naples Clinical Trials Unit.

Lancet Oncol. 2014 Nov;15(12):1379-88. doi: 10.1016/S1470-2045(14)70472-3. Epub 2014 Oct 15.


Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.

Paller CJ, Bradbury PA, Ivy SP, Seymour L, LoRusso PM, Baker L, Rubinstein L, Huang E, Collyar D, Groshen S, Reeves S, Ellis LM, Sargent DJ, Rosner GL, LeBlanc ML, Ratain MJ.

Clin Cancer Res. 2014 Aug 15;20(16):4210-7. doi: 10.1158/1078-0432.CCR-14-0521. Review.


NCIC CTG IND.190 phase I trial of dalotuzumab (MK-0646) in combination with cisplatin and etoposide in extensive-stage small-cell lung cancer.

Ellis PM, Shepherd FA, Laurie SA, Goss GD, Olivo M, Powers J, Seymour L, Bradbury PA.

J Thorac Oncol. 2014 Mar;9(3):410-3. doi: 10.1097/JTO.0000000000000058.


Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29.

Laurie SA, Solomon BJ, Seymour L, Ellis PM, Goss GD, Shepherd FA, Boyer MJ, Arnold AM, Clingan P, Laberge F, Fenton D, Hirsh V, Zukin M, Stockler MR, Lee CW, Chen EX, Montenegro A, Ding K, Bradbury PA.

Eur J Cancer. 2014 Mar;50(4):706-12. doi: 10.1016/j.ejca.2013.11.032. Epub 2013 Dec 17.


Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial).

Reaume MN, Leighl NB, Mittmann N, Coyle D, Hirsh V, Seymour L, Tu D, Shepherd FA, Graham B, Gridelli C, Perrone F, Di Maio M, Bradbury PA, Evans WK.

Lung Cancer. 2013 Oct;82(1):115-20. doi: 10.1016/j.lungcan.2013.07.012. Epub 2013 Aug 17.


An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib.

Hilton JF, Tu D, Seymour L, Shepherd FA, Bradbury PA.

Lung Cancer. 2013 Oct;82(1):136-42. doi: 10.1016/j.lungcan.2013.06.008. Epub 2013 Jul 31.


Differential role of estrogen receptor beta in early versus metastatic non-small cell lung cancer.

Navaratnam S, Skliris G, Qing G, Banerji S, Badiani K, Tu D, Bradbury PA, Leighl NB, Shepherd FA, Nowatzki J, Demers A, Murphy L.

Horm Cancer. 2012 Jun;3(3):93-100. doi: 10.1007/s12672-012-0105-y.


Genetic associations with sporadic neuroendocrine tumor risk.

Ter-Minassian M, Wang Z, Asomaning K, Wu MC, Liu CY, Paulus JK, Liu G, Bradbury PA, Zhai R, Su L, Frauenhoffer CS, Hooshmand SM, De Vivo I, Lin X, Christiani DC, Kulke MH.

Carcinogenesis. 2011 Aug;32(8):1216-22. doi: 10.1093/carcin/bgr095. Epub 2011 May 23.


Capecitabine or infusional 5-fluorouracil for gastroesophageal cancer: a cost-consequence analysis.

Horgan AM, Knox JJ, Liu G, Sahi C, Bradbury PA, Leighl NB.

Curr Oncol. 2011 Apr;18(2):e64-70.


An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer.

Horgan AM, Bradbury PA, Amir E, Ng R, Douillard JY, Kim ES, Shepherd FA, Leighl NB.

Ann Oncol. 2011 Aug;22(8):1805-11. doi: 10.1093/annonc/mdq682. Epub 2011 Jan 27.


Derivation of utility values from European Organization for Research and Treatment of Cancer Quality of Life-Core 30 questionnaire values in lung cancer.

Jang RW, Isogai PK, Mittmann N, Bradbury PA, Shepherd FA, Feld R, Leighl NB.

J Thorac Oncol. 2010 Dec;5(12):1953-7.


Plasma transforming growth factor alpha and amphiregulin protein levels in NCIC Clinical Trials Group BR.21.

Addison CL, Ding K, Zhao H, Le Maître A, Goss GD, Seymour L, Tsao MS, Shepherd FA, Bradbury PA.

J Clin Oncol. 2010 Dec 20;28(36):5247-56. doi: 10.1200/JCO.2010.31.0805. Epub 2010 Nov 15.


Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: potential regulation by targeting rho proteins.

Zhao TT, Le Francois BG, Goss G, Ding K, Bradbury PA, Dimitroulakos J.

Oncogene. 2010 Aug 19;29(33):4682-92. doi: 10.1038/onc.2010.219. Epub 2010 Jun 21.


Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.

Bradbury PA, Tu D, Seymour L, Isogai PK, Zhu L, Ng R, Mittmann N, Tsao MS, Evans WK, Shepherd FA, Leighl NB; NCIC Clinical Trials Group Working Group on Economic Analysis.

J Natl Cancer Inst. 2010 Mar 3;102(5):298-306. doi: 10.1093/jnci/djp518. Epub 2010 Feb 16.


Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes.

Bradbury PA, Kulke MH, Heist RS, Zhou W, Ma C, Xu W, Marshall AL, Zhai R, Hooshmand SM, Asomaning K, Su L, Shepherd FA, Lynch TJ, Wain JC, Christiani DC, Liu G.

Pharmacogenet Genomics. 2009 Aug;19(8):613-25. doi: 10.1097/FPC.0b013e32832f3010.


Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis.

Bradbury PA, Zhai R, Ma C, Xu W, Hopkins J, Kulke MJ, Asomaning K, Wang Z, Su L, Heist RS, Lynch TJ, Wain JC, Christiani D, Liu G.

Clin Cancer Res. 2009 Jul 15;15(14):4680-5. doi: 10.1158/1078-0432.CCR-09-0192. Epub 2009 Jul 7.


p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis.

Cescon DW, Bradbury PA, Asomaning K, Hopkins J, Zhai R, Zhou W, Wang Z, Kulke M, Su L, Ma C, Xu W, Marshall AL, Heist RS, Wain JC, Lynch TJ Jr, Christiani DC, Liu G.

Clin Cancer Res. 2009 May 1;15(9):3103-9. doi: 10.1158/1078-0432.CCR-08-3120. Epub 2009 Apr 21.


Matrix metalloproteinase 1, 3 and 12 polymorphisms and esophageal adenocarcinoma risk and prognosis.

Bradbury PA, Zhai R, Hopkins J, Kulke MH, Heist RS, Singh S, Zhou W, Ma C, Xu W, Asomaning K, Ter-Minassian M, Wang Z, Su L, Christiani DC, Liu G.

Carcinogenesis. 2009 May;30(5):793-8. doi: 10.1093/carcin/bgp065. Epub 2009 Mar 25.


Immunotherapy for lung cancer.

Bradbury PA, Shepherd FA.

J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S164-70. doi: 10.1097/JTO.0b013e318174e9a7. Review.


A rapid outcomes ascertainment system improves the quality of prognostic and pharmacogenetic outcomes from observational studies.

Bradbury PA, Heist RS, Kulke MH, Zhou W, Marshall AL, Miller DP, Su L, Park S, Temel J, Fidias P, Sequist L, Lynch TJ, Wain JC, Shepherd FA, Christiani DC, Liu G.

Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):204-11. doi: 10.1158/1055-9965.EPI-07-0470.


Chemotherapy and surgery for operable NSCLC.

Bradbury PA, Shepherd FA.

Lancet. 2007 Jun 9;369(9577):1903-4. No abstract available.


DNA repair pathways in drug resistance in melanoma.

Bradbury PA, Middleton MR.

Anticancer Drugs. 2004 Jun;15(5):421-6. Review.


Time judgment and body temperature.

Fox RH, Bradbury PA, Hampton IF, Legg CF.

J Exp Psychol. 1967 Sep;75(1):88-96. No abstract available.


Resting metabolism in man at elevated body temperatures.

Bradbury PA, Fox RH, Goldsmith R, Hampton IF, Muir AL.

J Physiol. 1967 Apr;189(2):61P-62P. No abstract available.




J Physiol. 1964 Jun;171:384-96. No abstract available.

Supplemental Content

Loading ...
Support Center